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INTRODUCTION
Medical imaging provides information for
diagnosis and staging, evaluation of treat-
ment response, and also plays pivotal role
in advanced radiotherapy treatment plan-
ning. In the era of the innovative conven-
tional and functional imaging techniques,
the main goal of radiation therapy, which
is to maximize the dose to the target while
minimizing the dose to adjacent healthy
organs, can be actualized. On the basis of
this, accurate delineation has led to the safe
decrease of radiotherapy volumes, in terms
of resulting in a reduced risk of normal tis-
sue toxicity, and increasing tumor control
probability (De Ruysscher et al., 2005; van
Der Wel et al., 2005).
Computed tomography (CT) is the
primary modality for image-based treat-
ment planning, but conventional anatomic
imaging with CT has limited sensitivity to
identify distinctly the anatomic borders of
the tumor (Nestle et al., 2009). Integration
of multimodality imaging data for radio-
therapy treatment planning is beneficial
and indespensable for perfect delineation
(Kessler et al., 1991; Rosenman et al.,
1998).
Currently, several studies showed that
positron emission tomography–computed
tomography (PET/CT) is significantly
used for staging for various type of tumor.
PET/CT combines biological activity and
anatomical information in a single study
session, and provides to distinguish viable
tumor focus. The use of PET/CT for
fused images with planning CT (pCT)
may allow adequate tumor visualization
(De Ruysscher et al., 2005; van Der
Wel et al., 2005). Otherwise, implementa-
tion of PET/CT information for radiation
therapy planning (RTP) to accurate delin-
eation is under investigation, but is not
recommended for a routine procedure. In
this paper, we focus on the clinical adop-
tion of PET/CT and the use of PET/CT
in RTP.
THE ROLE OF PET/CT IN TARGET
DEFINITION
PET/CT is preferred medical imaging
modality for detecting atelectasis from
intratumor heterogeneity in non-small cell
lung cancer, and has higher sensitivity
and specificity for identifying lymph node
involvement (Nestle et al., 1999). In sev-
eral planning studies, it was shown that
the addition of PET/CT information is
associated with smaller size on tumor vol-
ume than compared with radiotherapy
pCT (Bradley et al., 2004; Hanna et al.,
2010; Moller et al., 2011), thus radiation
oncologists enable to allow dose escala-
tion with slightly lower doses on organs
at risk with promising high curability
rates. The problem of target motion is
an important topic for lung and other
thoracicmalignancies. Respiratory motion
can cause artifacts that potentially deterio-
rate the quality of images and the appear-
ance of tumor with resulting misdiagnosis
and mislocalization (Nehmeh et al., 2002;
Nehmeh and Erdi, 2008). Nowadays, the
use of gated PET/CT and 4-dimensional
CT acquisition are becoming more popu-
lar for this aspect.
The use of FDG-PET has become
standard in the management of both
non-Hodgkin’s and Hodgkin’s lymphoma
with its high sensitivity for defining dis-
ease (Jerusalem et al., 1999; Kostakoglu
and Goldsmith, 2000). PET/CT has a
well-accepted role on staging, radiation
therapy field design and response evalu-
ation in lymphoma patients and may be
predict disease outcome. Recent findings
showed that staging with PET/CT is supe-
rior than CT or MRI. PET/CT influences
in involved field radiation therapy field
design in Hodgkin’s lymphoma and its
essential use leads to help to reduce target
volumes while protecting geographic miss
(Jerusalem et al., 1999; Mikhaeel et al.,
2005). Information provided by PET/CT
has distinguished between viable tumor
and fibrosis in residual mass during active
follow-up.
Although FDG-PET has a low sensi-
tivity for detecting involvement of lymph
nodes in early stage cervical carcinoma,
it is essential to determine the lymphatic
spread especially in para-aortic region
for locally advanced disease (Dolezelova
et al., 2008). In recent years, it was shown
that PET/CT affects radiotherapy planning
by tailoring field design and customizing
the radiation dose (Salem et al., 2011).
PET/CT based brachytherapy optimiza-
tion allows improved tumor volume dose
distribution without significantly increas-
ing the dose to the surrounding organs
(Lin et al., 2007).
Because of the high back-ground glu-
cose metabolism of normal gray mat-
ter structures, PET/CT with amino acid
tracers is used for primary brain tumors
instead of FDG-PET. In several stud-
ies, it was shown that integration of
PET/CT may discriminate active tumor
and radionecrosis, andmay improve delin-
eation skills and may help to evalu-
ate response after completion of therapy
(Ogawa et al., 1993).
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Also, PET/CT is recommended medi-
cal imaging technique in head and neck
cancer, with the advantage of defining
disease, nodal status and distant metas-
tases. PET/CT is considered a complemen-
tary technique to facilitate the delineation
skills on gross tumor volume and to iden-
tify nodal status of head and neck cancer
(Minn et al., 2010; Zygogianni et al., 2012).
PET/CT has a higher specificity for
detecting occult metastases and distant
nodal involvement in esophageal tumors,
by contrast, has a lower sensitivity than
compared with the use of combined endo-
scopic ultrasound guided CT for iden-
tifying lymph nodes which are adjacent
to tumor (Mujis et al., 2010). In this
regard, PET/CT provides improved stag-
ing opportunity, determines extensiveness
of disease and supports for treatment deci-
sion making, but its use for RTP is limited.
The role of PET/CT in rectal can-
cers is limited and further studies are
needed for a clear data. As evidence accu-
mulates that positive predictive value of
PET/CT is high for detecting lymph node
involvement instead of its lower sensitivity,
radiotherapy fields should be encompass
that regions, this situation should not be
ignored (Kantorova et al., 2003).
THE USE OF DIAGNOSTIC PET/CT FOR
IMAGE ACQUSITION AND
REGISTRATION
The diagnostic PET/CT is acquired with
the patient’ arms raised above and laid
down a curved couch top. Whereas, the
radiotherapy simulation CT images are
obtained in a procedure with the patient
lying on a flat table. For appropriate fusion
images, PET/CT should be performed in
RTP position to prevent recumbent posi-
tion related errors. For this purpose, a
second acquisition of PET/CT scan is not
acceptable because of the over radiation
exposure and additional cost. To solve this
issue clinicians use the benefits and func-
tions of improved radiotherapy planning
systems.
Correct registration is required to
strictly identify gross tumor volume.
Rigid and deformable image registra-
tions are the most commonly used sub-
types of registration, both can be done
in our center by using Velocity Advance
Image (AI) Software (Velocity Medical
Solutions, Version 2.7, Atlanta, GA). Rigid
registration is the overlap of the two image
data set based on bony structures. But,
the potential differences between image
data set, such as variations in anatom-
ical positioning, are still continued by
rigid fusion. The probability of mismatch
between PET/CT and pCT caused by
different recumbent position, unintended
organ movements and different respira-
tory phases is still disadvantage of rigid
fusion. It is well known that if the diagnos-
tic PET/CT is acquired the patient lying on
a flat table like RTP position, the accuracy
of rigid registration increases (Nestle et al.,
1999). Whereas in clinical use this proce-
dure is not routine. This requirement has
led to the development of deformable reg-
istration approaches. Deformable image
registration ensures to reduce geomet-
ric differences between the two image
data sets, by estimating the spatial rela-
tionship between the volume elements
of corresponding structures. Deformable
registration can be executed automatically
by using “Navigation” tool which is in the
new version or by two steps, initially man-
ually alignment for rigid registration, and
then choosing “region of interest” area.
Thus, a new close to real image is obtained
by this algorithm. Deformable registra-
tion has been demonstrated to improve
the accuracy of diagnostic PET/CT fusion
in head and neck patients, but it is rec-
ommended to be careful on delineating
tumors in neck region (Hwang et al.,
2009).
THRESHOLD SEGMENTATION
The most commonly used PET tracer is
18-F fluorodeoxyglucose (18 F-FDG). The
standardized uptake value (SUV) is often
used for quantitative analysis of PET and
shows the biological activity. Due to the
knowledge of the highest FDG uptake area
in the pre-treatment session has the high-
est risk for local recurrence after ther-
apy, some authors suggested that improved
local control rates can be obtained by
intensifying radiation dose to that areas
(Abramyuk et al., 2009). This assessment
is significantly important because of allow-
ing better ratios of curability by escalating
the dose to the active tumor as well as
lowering toxicity by reducing the dose to
critical organs. However, the problem of
this setting is still unknown which SUV
threshold is appropriate, further studies
investigated to define optimal SUV lev-
els for many cancers (Wang et al., 2012).
Identifying the volume of each SUV is
not possible manually, so that automati-
cally tools are required for practical use
by Velocity AI. The delineated volumes
should be checked on the pCT images
and parts of overlapping on bony and airy
structures should be deleted.




(SRS) and stereotactic body radiother-
apy (SBRT) are advanced radiotherapy
techniques which have high degrees of
precision. Delivery of high doses to tar-
get volume, and limiting the dose to the
adjacent normal tissues by rapid dose fall-
off, the new stereotactic techniques are
effective and safe. Currently, this novel
technology gained experience in many
type of cancer management in a short time
interval, and accepted therapy for a wide
range of indications. So, perfect delin-
eation skills are required to deliver doses
of radiation with high accuracy. In this
context, PET/CT takes place for defining
tumor volume in stereotactic approaches.
THE IMPACT OF PET/CT ON
INTEROBSERVER AND
INTRAOBSERVER VARIABILITIES
Inspite of ongoing developments in
diagnostic imaging and advances on
radiotherapy treatment planning, radi-
ation oncologists still manually contour
the tumor, and this component is sig-
nificantly related with interobserver and
intraobserver contouring variabilities.
This well-defined uncertainty is operator-
dependent process that influences target
volume and modifies the treatment plan.
With the use and interpretation of medi-
cal imaging techniques, improvement on
interobserver and intraobserver agree-
ment is demonstrated in several studies
(Mah et al., 2002). PET/CT increases
the interobserver agreement on tumor
delineation, aids to avoid geographical
misses (Steenbakkers et al., 2006; Buijsen
et al., 2012). Also by using these auto-
matic tools mentioned above interobserver
and intraobserver variabilities for tumor
delineation are reduced.
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FIGURE 1 | Displayed the assessment graphic containing the data obtained by the comparison of pre-treatment vs. post-treatment PET/CT findings
by using Velocity AI “Navigation” tool.
ASSESSMENT OF PRE-TREATMENT vs.
POST-TREATMENT PET/CT FINDINGS
PET/CT provides data for evaluation of
tumor response for aforementioned types
of cancer after completion of therapy.
PET/CT is accepted modality for evalu-
ation of treatment response in various
types of cancer by means of distinguish-
ing tumor progression, regression or stable
disease. We have opportunity to compare
the difference between the two images,
pre-treatment vs. post-treatment PET/CT,
and to obtain an assessment graphic by
using Velocity AI “Navigation” tool. This
dose-SUV histogram is instructive for clin-
icians to interpret PET/CT findings and to
compare tumor biology (Figure 1).
CONCLUSION
Radiation therapy plays a key role in
the management of cancer treatment.
The main objective of radiotherapy is to
achieve improved local control with dose
escalation to the tumor while decreasing
the probability of side effects by reduc-
ing radiation exposure to healthy sur-
rounding organs. Accurate delineation is
required for correct definition of gross
tumor volume to avoid undertreatment.
CT based RTP just includes anatomi-
cal information, is insufficient for this
aspect, thus advanced imaging techniques
have gained critical importance. PET/CT
is increasingly being used one of the
medical imaging for this purpose that
combines the metabolic and anatomic
features. PET/CT is accepted modality
for diagnosis, staging, and assessment of
tumor response in various types of cancer.
There are growing data about comparing
the use of PET/CT vs. other imaging
techniques for RTP, moreover, contro-
versy exists about the appropriate use of
PET/CT. Finally, the evaluation of PET/CT
images is beneficial for accurate delin-
eation and also a complementary method
to determine target volumes in radio-
therapy. By employing PET/CT informa-
tion with the capabilities of Velocity AI
as software based image co-registration,
threshold segmentation, response assess-
ment can be done practically in radiother-
apy planning and follow-up.
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